Paradigm Biocapital Advisors LP 13D and 13G filings for Viridian Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:33 pm Sale | 2024-09-30 | 13G | Viridian Therapeutics, Inc. VRDN | Paradigm Biocapital Advisors LP | 3,509,253 4.600% | -1,795,060 (-33.84%) | Filing |
| 2024-02-14 4:08 pm Purchase | 2023-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Paradigm Biocapital Advisors LP | 5,304,313 9.990% | 2,993,615 (+129.55%) | Filing |
| 2023-05-11 4:26 pm Purchase | 2023-05-01 | 13G | Viridian Therapeutics, Inc. VRDN | Paradigm Biocapital Advisors LP | 2,310,698 5.400% | 419,531 (+22.18%) | Filing |
| 2023-02-14 4:59 pm Purchase | 2022-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Paradigm Biocapital Advisors LP | 1,891,167 4.700% | 682,116 (+56.42%) | Filing |
| 2022-02-14 06:12 am Purchase | 2021-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Paradigm Biocapital Advisors LP | 1,209,051 5.570% | 1,209,051 (New Position) | Filing |